论文部分内容阅读
为探讨人乳头瘤病毒(Human papilloma virus,HPV)16 L1蛋白表达与宫颈癌发生与发展的关系,为防治宫颈癌奠定基础。采用收集宫颈癌患者48例、宫颈上皮内瘤样病变(cervcal intraepithelial neoplasia,CIN)患者41例和慢性宫颈炎患者30例石蜡组织标本用于免疫组织化学实验的方法。检测HPV16 L1蛋白在宫颈癌组织、CIN组织和慢性宫颈炎组织中的蛋白质表达状况。HPV16 L1蛋白质免疫组织化学实验的结果显示,慢性宫颈炎组织中阳性率为100%,而在宫颈癌组织中阳性率仅为27.1%,差异有统计学意义(P<0.01)。慢性宫颈炎组织的阳性率明显高于宫颈癌组织。由此可知,HPV16 L1蛋白质在宫颈原位癌开始表达减少,宫颈浸润癌表达减少更明显,可能可以用于诊断CINⅡ和CINⅢ或CINⅡ和宫颈癌。
In order to explore the relationship between the expression of human papilloma virus (HPV) 16 L1 protein and the occurrence and development of cervical cancer, and to lay the foundation for the prevention and treatment of cervical cancer. In this study, 48 cases of cervical cancer, 41 cases of cervical intraepithelial neoplasia (CIN) and 30 cases of chronic cervicitis were collected for immunohistochemistry. To detect the protein expression of HPV16 L1 protein in cervical cancer, CIN and chronic cervicitis. HPV16 L1 protein immunohistochemistry results show that the positive rate of chronic cervicitis tissue was 100%, while the positive rate in cervical cancer was only 27.1%, the difference was statistically significant (P <0.01). The positive rate of chronic cervicitis was significantly higher than that of cervical cancer. This shows that, HPV16 L1 protein in situ cervical cancer began to reduce the expression of reduced expression of invasive cervical cancer is more obvious, may be used to diagnose CIN Ⅱ and CIN Ⅲ or CIN Ⅱ and cervical cancer.